TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Stock Information for Maplebear Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Maplebear Inc.

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Protara Therapeutics to Participate in Upcoming Investor Conferences
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.